International Assets Investment Management LLC Takes $254,000 Position in Genmab A/S (NASDAQ:GMAB)

International Assets Investment Management LLC bought a new stake in Genmab A/S (NASDAQ:GMAB) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 10,410 shares of the company’s stock, valued at approximately $254,000.

Several other hedge funds also recently modified their holdings of the business. Allspring Global Investments Holdings LLC acquired a new stake in shares of Genmab A/S in the 1st quarter valued at approximately $43,000. Janney Montgomery Scott LLC raised its holdings in Genmab A/S by 43.2% during the 1st quarter. Janney Montgomery Scott LLC now owns 17,369 shares of the company’s stock worth $520,000 after buying an additional 5,238 shares during the period. Gallacher Capital Management LLC raised its holdings in Genmab A/S by 17.9% during the 1st quarter. Gallacher Capital Management LLC now owns 7,865 shares of the company’s stock worth $235,000 after buying an additional 1,192 shares during the period. Envestnet Portfolio Solutions Inc. raised its holdings in Genmab A/S by 2.3% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 27,755 shares of the company’s stock worth $830,000 after buying an additional 633 shares during the period. Finally, SG Americas Securities LLC raised its holdings in Genmab A/S by 360.5% during the 1st quarter. SG Americas Securities LLC now owns 29,500 shares of the company’s stock worth $882,000 after buying an additional 23,094 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Price Performance

GMAB stock opened at $22.33 on Thursday. The company has a fifty day moving average price of $24.57 and a two-hundred day moving average price of $26.47. Genmab A/S has a one year low of $21.90 and a one year high of $32.89. The stock has a market cap of $14.78 billion, a price-to-earnings ratio of 18.45, a price-to-earnings-growth ratio of 0.68 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The company had revenue of $779.50 million for the quarter, compared to the consensus estimate of $734.60 million. Research analysts anticipate that Genmab A/S will post 1.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on GMAB shares. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Wednesday, October 16th. Truist Financial dropped their target price on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, September 9th. Royal Bank of Canada raised shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th. Redburn Atlantic started coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They set a “buy” rating for the company. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $31.00 target price on shares of Genmab A/S in a research note on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.